红日药业9月17日获融资买入1388.05万元，融资余额6.45亿元

Group 1 - On September 17, Hongri Pharmaceutical experienced a decline of 1.28% with a trading volume of 202 million yuan, and the net financing buy was -7.32 million yuan [1] - As of September 17, the total margin balance for Hongri Pharmaceutical was 646 million yuan, with a financing balance of 645 million yuan, accounting for 5.55% of the circulating market value, which is below the 20th percentile level over the past year [1] - The company’s main business revenue composition includes 57.27% from traditional Chinese medicine formula granules and decoction pieces, 21.73% from Xuebijing injection, and 20.14% from smart supply chain for medical devices [1] Group 2 - As of June 30, the number of shareholders for Hongri Pharmaceutical was 100,800, a decrease of 2.01% from the previous period, while the average circulating shares per person increased by 1.98% to 27,160 shares [2] - For the first half of 2025, Hongri Pharmaceutical reported operating revenue of 2.795 billion yuan, a year-on-year decrease of 6.72%, and a net profit attributable to shareholders of 78.63 million yuan, down 46.95% year-on-year [2] - Since its A-share listing, Hongri Pharmaceutical has distributed a total of 1.116 billion yuan in dividends, with 270 million yuan distributed over the past three years [3]